{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:11:23Z","timestamp":1792098683201,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ophtha.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T19:15:28Z","timestamp":1592075728000},"page":"1663-1673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-3786","authenticated-orcid":false,"given":"Kimberly L.","family":"Spooner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-9359","authenticated-orcid":false,"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-2461","authenticated-orcid":false,"given":"Mariano","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2299-5251","authenticated-orcid":false,"given":"Giovanni","family":"Staurenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-1987","authenticated-orcid":false,"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-8178","authenticated-orcid":false,"given":"Davide","family":"Monteduro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.06.019_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye and Vision (London, England)"},{"issue":"24","key":"10.1016\/j.ophtha.2020.06.019_bib2","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ophtha.2020.06.019_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/phar.1264","article-title":"Age-related macular degeneration","volume":"33","author":"Cheung","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jcp.22708","article-title":"Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration","volume":"227","author":"Nagineni","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"issue":"12","key":"10.1016\/j.ophtha.2020.06.019_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s12325-013-0078-4","article-title":"Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration","volume":"30","author":"Johnston","year":"2013","journal-title":"Adv Ther"},{"issue":"9900","key":"10.1016\/j.ophtha.2020.06.019_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ophtha.2020.06.019_bib7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1167\/iovs.12-11073","article-title":"Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration","volume":"54","author":"Marsiglia","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.10-5619","article-title":"Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration","volume":"52","author":"Schmitz-Valckenberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/OED.S38863","article-title":"Association of anti-VEGF injections with progression of geographic atrophy","volume":"8","author":"Enslow","year":"2016","journal-title":"Ophthalmol Eye Dis"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ophtha.2020.06.019_bib13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","article-title":"Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)","volume":"123","author":"Bhisitkul","year":"2016","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.ophtha.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1167\/iovs.11-8353","article-title":"Expression and role of VEGF in the adult retinal pigment epithelium","volume":"52","author":"Ford","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ophtha.2020.06.019_bib15","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina (Phila)"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2020.06.019_bib17","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ophtha.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/bjophthalmol-2018-312430","article-title":"Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen","volume":"103","author":"Mantel","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2020.06.019_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IAE.0000000000002054","article-title":"Macular atrophy incidence in anti-vascular endothelial growth factor-treated neovascular age-related macular degeneration: risk factor evaluation for individualized treatment need of ranibizumab or aflibercept according to an observe-and-plan regimen","volume":"39","author":"Mantel","year":"2019","journal-title":"Retina (Phila)"},{"issue":"8","key":"10.1016\/j.ophtha.2020.06.019_bib20","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.06.019_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2020.06.019_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","article-title":"Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration","volume":"143","author":"Holz","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.06.019_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/eye.2013.275","article-title":"Predictors for the progression of geographic atrophy in patients with age-related macular degeneration: fundus autofluorescence study with modified fundus camera","volume":"28","author":"Jeong","year":"2014","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ophtha.2020.06.019_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ophtha.2016.12.002","article-title":"Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus meetings","volume":"124","author":"Holz","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2020.06.019_bib25","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1167\/iovs.10-5852","article-title":"Interpretations of fundus autofluorescence from studies of the bisretinoids of the retina","volume":"51","author":"Sparrow","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ophtha.2020.06.019_bib26","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1167\/iovs.04-0430","article-title":"Classification of fundus autofluorescence patterns in early age-related macular disease","volume":"46","author":"Bindewald","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ophtha.2020.06.019_bib27","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina (Phila)"},{"issue":"4","key":"10.1016\/j.ophtha.2020.06.019_bib28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/bjophthalmol-2015-308065","article-title":"Prevalence and quantification of geographic atrophy associated with newly diagnosed and treatment-naive exudative age-related macular degeneration","volume":"101","author":"Sikorav","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2020.06.019_bib29","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1167\/iovs.11-7457","article-title":"Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration","volume":"52","author":"Schmitz-Valckenberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2020.06.019_bib30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.iae.0000433986.32991.1e","article-title":"Evaluation of semiautomated measurement of geographic atrophy in age-related macular degeneration by fundus autofluorescence in clinical setting","volume":"34","author":"Panthier","year":"2014","journal-title":"Retina (Phila)"},{"issue":"4","key":"10.1016\/j.ophtha.2020.06.019_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2010.08.018","article-title":"Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography","volume":"118","author":"Yehoshua","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.06.019_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-015-0015-6","article-title":"Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration","volume":"1","author":"Dhrami-Gavazi","year":"2015","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of Age-Related Eye Disease Study report no. 26","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.06.019_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2020.06.019_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/IAE.0000000000002402","article-title":"Macular atrophy in neovascular age-related macular degeneration: a pilot post hoc analysis of patients with pigment epithelial detachments","volume":"40","author":"Rebhun","year":"2020","journal-title":"Retina (Phila)"},{"issue":"6","key":"10.1016\/j.ophtha.2020.06.019_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ophtha.2019.11.016","article-title":"Incidence of macular atrophy after untreated neovascular age-related macular degeneration: Age-Related Eye Disease Study report 40","volume":"127","author":"Christakis","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2020.06.019_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2020.06.019_bib38","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2020.06.019_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","article-title":"Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration","volume":"4","author":"Pfau","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"10.1016\/j.ophtha.2020.06.019_bib40","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/IAE.0000000000001765","article-title":"Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration","volume":"38","author":"Kuroda","year":"2018","journal-title":"Retina (Phila)"},{"issue":"6","key":"10.1016\/j.ophtha.2020.06.019_bib41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR Study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2020.06.019_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/tvst.7.6.40","article-title":"The rate of progression of geographic atrophy decreases with increasing baseline lesion size even after the square root transformation","volume":"7","author":"Mones","year":"2018","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN Trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ophtha.2020.06.019_bib44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.iae.0000230717.85319.f5","article-title":"Safety of intravitreal injection of bevacizumab in rabbit eyes","volume":"26","author":"Feiner","year":"2006","journal-title":"Retina (Phila)"},{"issue":"1","key":"10.1016\/j.ophtha.2020.06.019_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajo.2006.03.058","article-title":"Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model","volume":"142","author":"Bakri","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2020.06.019_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1389200216666151001120831","article-title":"Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection","volume":"16","author":"Semeraro","year":"2015","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ophtha.2020.06.019_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","article-title":"Treatment-naive quiescent choroidal neovascularization in geographic atrophy secondary to nonexudative age-related macular degeneration","volume":"182","author":"Capuano","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.06.019_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000361077","article-title":"Geographic atrophy progression in eyes with age-related macular degeneration: role of fundus autofluorescence patterns, fellow eye and baseline atrophy area","volume":"52","author":"Batioglu","year":"2014","journal-title":"Ophthalmic Res"},{"issue":"5","key":"10.1016\/j.ophtha.2020.06.019_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.7.5.13","article-title":"Comparison of green versus blue fundus autofluorescence in ABCA4-related retinopathy","volume":"7","author":"M\u00fcller","year":"2018","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"10.1016\/j.ophtha.2020.06.019_bib50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00347-016-0228-6","article-title":"[Long-term results in neovascular age-related macular degeneration: changes in visual acuity and geographic atrophy during long-standing anti-VEGF therapy]","volume":"113","author":"Thalgott","year":"2016","journal-title":"Ophthalmologe"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202030556X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202030556X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:10:10Z","timestamp":1758982210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202030556X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S016164202030556X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.019","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}